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the CC BY-NC-ND license (http://creaAbstract Prostate cancer (PCa) is the most common cause of malignancy in males and the
second leading cause of cancer mortality in United States. Current treatments for PCa include
surgery, radiotherapy, and androgen-deprivation therapy. Eventually, PCa relapses to an
advanced castration-resistant PCa (CRPC) that becomes a systematic disease and incurable.
Therefore, identifying cellular components and molecular mechanisms that drive aggressive
PCa at early stage is critical for disease prognosis and therapeutic intervention. One potential
strategy for aggressive PCa is to target cancer stem cells (CSCs) that are identified by several
unique characteristics such as immortal, self-renewal, and pluripotency. Also, CSC is believed
to be a major factor contributing to resistance to radiotherapy and conventional chemother-
apies. Moreover, CSCs are thought to be the critical cause of metastasis, tumor recurrence
and cancer-related death of multiple cancer types, including PCa. In this review, we discuss
recent progress made in understanding prostate cancer stem cells (PCSCs). We focus on the
therapeutic strategies aimed at targeting specific surface markers of CSCs, the key signaling
pathways in the maintenance of self-renewal capacity of CSCs, ATP-binding cassette (ABC)
transporters that mediate the drug-resistance of CSCs, dysregulated microRNAs expression
profiles in CSCs, and immunotherapeutic strategies developed against PCSCs surface markers.
ª 2016 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer (PCa) is the most frequently diagnosed
cancer and has the second highest mortality rate amongestern.edu (J.T. Hsieh).
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most diagnosed cancers worldwide, especially in western
developed countries [1]. Recently, the incidence and mor-
tality rate of PCa rose significantly in several Asian countriesity.
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204 E.J. Yun et al.such as Japan, Korea and China [1]. At the early stage, PCa
is multi-focal and can be managed effectively by surgery,
high-intensity focused ultrasound therapy (HIFU), or
radiotherapy. However, the advanced-stage of PCa, char-
acterized by acquisition of invasive phenotypes, leading to
bone metastases, is generally incurable [2]. It is becoming
increasingly clear that heterogeneous tumor cell pop-
ulations, which may arise from different cancer stem cells
(CSC) subpopulations, are hierarchically organized. CSCs
were first described in acute myeloid leukemia [3], and
later, were also identified in various solid tumors including
PCa [4]. CSCs are defined as small subsets of cells within a
tumor that are highly tumorigenic with unlimited self-
renewal capacity and can also regenerate non-tumorigenic
progeny. Particularly, CSCs seem to be more resistant than
differentiated tumor cells to conventional therapies [5,6].
Therefore, the CSC theory is likely to facilitate the under-
standing of tumor progression and expedite the develop-
ment of effective therapeutic strategies targeting CSCs.
Here, we review the current knowledge of CSCs and the
relationship between CSCs and metastatic castration-
resistant prostate cancer (CRPC). In addition, we will
address the therapeutic implications and challenges for
targeting CSCs and discuss emerging and innovative ap-
proaches for the treatment of CRPC. Understanding the link
between CSCs and metastatic CRPC will facilitate the
development of novel therapeutic approaches and improve
the clinical outcomes of PCa patients.
2. Normal prostate stem cells and CSCs
Stem cells have been defined as cells that have the ability to
perpetuate themselves through self-renewal and to differ-
entiate into mature tissue types [7,8]. Self-renewal is
crucial to stem cell function, because it is required for stem
cells to persist for the lifetime of the animal. Moreover,
while stem cells from different organs may vary in their
developmental potential, all stem cells must self-renew and
regulate the relative balance between self-renewal and
differentiation. While CSCs are not necessarily derived from
normal stem cells, this fraction of tumor cells possesses
many functional similarities with normal stem cells (NSCs)
such as self-renewal capacity and pleuripotency [9].
Therefore, understanding the regulation of NSC is also
fundamental to understanding the regulation of CSCs.
The normal prostate epithelial stem cell differentiates
into three epithelial cell types, basal, luminal, and rare
neuroendocrine [10]. Basal cells express high molecular
weight cytokeratin (CK) including CK5 and CK14, and also
Bcl-2, CD44, p63 but not androgen receptor (AR) [11e13].
Terminally differentiated luminal cells express low molec-
ular weight CK such as CK8, CK18 and also express AR [12].
Luminal cells secrete prostate-specific antigen (PSA) and
prostate-specific alkaline phosphatase (PAP) into the glan-
dular lumen in an androgen-dependent manner. Unlike the
majority of secretory luminal cells, neuroendocrine (NE)
cells express synaptophysin and chromogranin A, but not AR
or PSA and also secrete neuropeptides including serotonin,
bombesin, calcitonin and somatostatin [10,14].
Androgen-deprivation of rodent models provides evi-
dence for the presence of normal prostate stem cells(NPSCs) within the basal compartment of the prostate
gland. Basal cells preferentially survive during castration
whereas most of the luminal cells are lost through pro-
grammed cell death [15,16]. However, the cellular origin of
the NPSCs is not always certain. For example, the luminal
population of castration-resistant Nkx3.1-expressing cells
(CARNs) express CK18 and AR but not basal markers [17] and
these cells exhibit stem cell characteristics and can
regenerate prostatic tissue after androgen replacement
[17]. In addition, the cellular origins of PCa remain a sub-
ject of debate. In mouse models, it has been shown that
basal and luminal populations can both serve as cells of
origin for PCa [18,19], however, only basal cells have been
shown to be efficient targets for transformation in human
PCa [20]. Also, in vivo, PCa with stem cell characteristics
survive castration, express a luminal progenitor phenotype
with low AR expression, and possess tumor-initiating po-
tential after androgen replacement [21]. In contrast, PCSCs
may also be derived from NSCs with malignant trans-
formation because CRPC is androgen-independent and
basal cells can be identified from a majority of metastasis
[22]. In addition, some key molecules that normally regu-
late self-renewal and survival of NSCs (e.g. p63, Bcl-2, and
hTERT) are preferentially localized in basal compartment
[12,14]. However, human PCa has a markedly luminal
phenotype which has led to the idea that PCa arises from a
fully differentiated luminal cell. Shen et al. [23] demon-
strated that CARNs, which are a luminal stem cell popula-
tion, are a cell type of origin for certain types of PCa. Also,
a recent study showed that both populations of CD49fhi
basal cells and CD26hi luminal cells generated a mixture of
CK5þ basal cells and CK8þ luminal cells. However, only
purified luminal cells could generate organoids with a
glandular architecture under established organoid culture
conditions, suggesting that luminal stem cells are capable
of regenerating the normal glandular architecture of human
prostate [24].
Another possible origin of PCSCs might be through cell
fusion between stem cells and other types of cells
including differentiated cells, stromal cells, or inflam-
matory cells [25]. Cell fusion may allow for the combi-
nation of self-renewal properties of NSCs with the
accumulated mutations in differentiated cells to attain a
fully neoplastic transformation. As an example, it has
been shown that bone marrow derived cells can fuse with
neoplastic epithelium to promote tumor development and
metastasis through creation of CSCs [26]. Although the
origin of PCSCs still remains controversial, it is also
possible that PCa might have acquired CSCs features
through genetic/epigenetic changes.
3. Isolation and identification of PCSCs
Hematopoietic stem cell markers have provided the para-
digms for identifying and isolating CSCs in solid tumors
including PCa [27,28]. In prostate, the biomarkers CD44,
stem cell antigen (Sca-1), CD133 (prominin-1), and ABCG2
are commonly used for fluorescence-activated cell sorting
(FACS) to isolate NSCs [14,19,29]. A unique PCSC marker(s)
has not yet been found, although certain markers of
“stemness” that are generally present in various NSCs and
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face receptor involved in cellecell interactions and in cell
adhesion and migration [30]. CD44þ PCa cells displayed
increased proliferation, tumorigenicity, and metastatic
potential compared to CD44 cells [31]. Furthermore,
CD44þ cells could initiate serially passed prostaspheres and
serially transplantable tumors suggesting high self-renewal
potential [31]. Another study also showed a similar result;
CD44þ/CD24 cells formed prostaspheres consistently
in vitro, and CD44þ/CD24 xenografts initiated tumors
in vivo with the injection of small number of cells [32]. The
Sca-1 is expressed by stem or progenitor cells in various
tissues, and has been used to enrich for murine hemato-
poietic stem cells [33]. Sca-1þ cells exhibited increased
proliferated capacity, with a subpopulation of Sca-1þ cells
also expressing Bcl-2 and integrin a6 [18]. Another stem cell
marker, CD133, is expressed in hematopoietic stem cells
and has long been used to identify CSCs. CD133þ prostate
cells display stem cell features such as prostasphere for-
mation and development of prostatic-like acini in immu-
nocompromised male mice [29]. In addition, CD133þ cells
also co-express CK14 or hTERT and gave rise to more and
larger branching ducts consisting of luminal and basal
epithelial cells compared to CD133 cells [34]. The ATP-
binding cassette (ABC) membrane transporter, ABCG2,
expressed in these cells, enables the efflux of Hoechst
33342 dye suggesting the association of these cells with
multidrug resistance [35]. Aldehyde dehydrogenease
(ALDH) is an enzyme involved in intracellular retinoic acid
production; in PCSCs, high expression of ALDH1A1 was
found to be positively correlated with Gleason score and
pathologic stage but inversely correlated with overall sur-
vival, indicating that it may be a potential PCSC marker
[36]. Combining multiple markers has also improved the
isolation of PCSCs. CD44þ a2b1high CD133þ cell populations
possessed a significant capacity for self-renewal and could
regenerate the phenotypically mixed populations of non-
clonogenic cells [37]. Another study also demonstrated
that the CD44þ a2b1high populations from LAPC-9 tumor
xenografts showed tumorigenic potential [38].
As mentioned, the most well-known CSC markers are
commonly associated with a variety of NSCs. Therefore,
these markers could be utilized, in combination with
negative selection against differentiation markers, toTable 1 Markers associated with PCSC.
Stem cell marker Reference
CD44 Patrawala et al. [31,38]
CD24 Hurt et al. [32]
Sca-1 (stem cell antigen-1) Lawson et al. [19],
Xin et al. [18]
CD133 (prominin-1) Richardson et al. [29],
Collins et al. [37]
ABCG2 Patrawala et al. [35]
a2b1 Collins et al. [35],
Patrawala et al. [38]
CD49f (integrin a6) Lawson et al. [19]
Nanog/Sox2/Oct4/Lin28B Guzman-Ramirez et al. [55]
PCSC, prostate cancer stem cells.isolate and characterize CSCs from different malignancies.
Most importantly, the identification of PCSC specific marker
would facilitate the development of tailored drugs to cure
PCa.
4. Conventional therapeutic approaches and
CSCs
Androgen deprivation therapy (ADT) is the gold standard
regimen for metastatic PCa patients. However, ADT only
targets androgen-sensitive PCa cells, and most patients
relapse and eventually progress to CRPC after the initial
response [39]. Conventional anticancer therapies including
chemotherapy, radiation and immunotherapy also kill
rapidly growing differentiated tumor cells [5]. Since current
anticancer therapies fail to eradicate CSCs, only half of the
patients respond to chemotherapy and even those who
initially respond to treatment eventually become resistant
[40].
In general, CRPC exhibits a phenotype similar to the NSCs
[41], suggesting that a clonal expansion of small PCSC pop-
ulation from the original tumor and/or de-differentiation of
PCa leads to PCSC. It has been shown that NSCs from various
tissues tend to be more resistant to chemotherapy than
mature cell types from same tissues [42]. The mechanisms
for this are not clear yet, however, several lines of evidence
are suggestive of possible mechanisms. For instance, the
dormant status of PCSCs has been thought to reduce their
susceptibility to chemotherapy. ABC transporters are mem-
brane transporters that can efflux various distinct and
structurally unrelated small molecules out of cells [35]. Like
hematopoietic stem cells, NPSCs and PCSCs appear to ex-
press high levels of ABC transporters; such as ABCG2, which
can also serve as markers for PCSCs [35]. The presence of
these proteins can increase the changes of efflux of cyto-
toxic chemotherapeutics from the cells, thereby making
them resistant. High expression of ABC transporters in PCSCs
can be determined by dye exclusion assay with Hoechst
33342 [43]. Within a solid tumor, there are small populations
of cells, called side population (SP) that demonstrate
increased efflux of the Hoechst dye [43]. Accumulated evi-
dence showed that this cell population possesses similar
characteristics to CSCs. Zhang et al. [44] showed prosta-
spheres exhibiting CSC phenotype were highly chemo-
resistant and had high levels of expression of a member of
the ABC transporter family, ABCG2. Moreover, expression of
ABCG2 is regulated by many CSC associated signaling path-
ways such as Hedgehog, Notch and PTEN/PI3K/AKT pathway
[45e47]. In addition, apoptotic signaling pathways are also
deregulated in CSCs [48] with high expression of anti-
apoptotic molecules and reduced expression of pro-
apoptotic genes such as, Bcl-2, Bcl-XL and Mcl-1 [48]. In a
CD133þ glioma, CSCs express a high level of Bcl-2 and Bcl-XL,
and high expression of Mcl-1 correlates with resistance to
Bcl-2 inhibitor [49]. In PCa, our recent data indicate that
cluster in, an anti-apoptotic chaperone, is responsible for
generating chemo-resistant PCa cells that exhibit CSC phe-
notypes [50]. Also, CSCs exhibit preferential activation of
the DNA damage repair system that may also contribute to
chemoresistance as well as radioresistance [6]. Several
studies have demonstrated that CSCs enriched under
206 E.J. Yun et al.selective culture conditions, enhanced DNA damage repair
signaling such as those through the ATR-Chk1 and Chk2
[6,51].
Collectively, current chemotherapy and radiotherapy
fail to eliminate the PCSC population because they do not
aim for the “Achilles’ heel” of PCSC. Therefore, it is
necessary to develop CSC therapy by specifically targeting
PCSCs. Direct targeting PCSCs along with fast-growing
progeny may increase therapeutic efficacy and prevent
tumor recurrence.
5. Therapies targeting CSCs
A small population of CSCs, which are involved in tumor
initiation, maintenance, metastasis and recurrence, often
contribute to the treatment failure and cancer relapse
after chemotherapy, radiotherapy and other conventional
therapies against cancer. Therefore, it is of critical impor-
tance to develop therapeutic strategies that can specif-
ically eradicate CSC populations and prevent tumor relapse
after long term clinical treatment. CSCs possess several
unique properties such as presenting of specific surface
markers, slow cell division rate, efficient DNA repair ma-
chinery, highly expressed drug-efflux pumps, distinct
miRNA expression profile, as well as existing in a hypoxia
and acidosis microenvironment. Based on these CSCs
characteristics, multiple strategies have been developed to
eliminate the CSC niche in the tumor by targeting CSC
surface markers, manipulating signaling pathways that
would lead to CSC apoptosis and differentiation, inhibiting
drug-efflux pumps, modulating critical miRNA levels, and
adjusting the crosstalk with tumor microenvironment
stimulants.
5.1. Targeting CSC markers
PCa also contains rare stem-like cell populations respon-
sible for tumor formation and maintenance. Identification
of specific markers presented by these PCSCs is therefore,
important for precise isolation of PCa tumor-initiating cells.
In particular, a2 and a6 integrins with CD44 and CD133 are
often identified in PCSCs. By using patient-derived PCa
tissue sample, Colombel et al. [52] found that tumors with
higher level of c-met, integrin a2 and a6 were positively
associated with the occurrence of bone metastasis in PCa
patients. Meanwhile, by examining bone marrow samples
from different stages of PCa patients, Ricci et al. [53] also
identified that the presence of c-met-, integrin a2- and a6-,
and CD45-positive cells is significantly associated with the
risk of metastasis and cancer lethality in PCa patients. Both
studies indicate that bone metastases could be the end
result of PCSCs dissemination from primary tumors [52,53].
Moreover, Guzel et al. [54] demonstrated that SOX2, OCT4,
KLF4 and ABCG2 expression were highly enhanced in
recurrent human PCa tissue, compared to non-recurrent
ones, suggesting that the increased stem cell-like PCa cell
population may contribute to chemoresistance and recur-
rence of PCa. In an earlier study, Collins et al. [37] iden-
tified and characterized a population of PCSCs in human
PCa tumors that possess significant self-renewal capacity
and express CSCs markers such as CD44, a2b1 integrin andCD133. Moreover, Guzma´n-Ramı´rez et al. [55] demon-
strated that the prostaspheres propagated from human PCa
tumors exhibit CSCs markers such as CD133, Nestin, and
CD44 in addition to NSC markers such as Oct-4, Nanog,
Bmi-1, and Jagged-1. Overall, these studies suggest that
the enriched neoplastic cells in the prostasphere derived
from human PCa specimens possess self-renewal and clo-
nogenic potential.
5.2. Targeting key signaling pathways involving
CSCs maintenance
CSCs typically display highly activation of one or more
conserved signal transduction pathways involved in organ
development and tissue homeostasis including the
Hedgehog (HH), Notch, and Wnt pathways [56]. Increasing
evidence demonstrates that those developmental signal
pathways can interact with other cellular signaling path-
ways such as PI3K, MAPK, and NF-kB. And deregulation of
these self-renewal pathways often occur in CSCs, which
allow for drug resistance and relapse. Current cancer
treatment strategies using nanoformulation of small mol-
ecules may provide advantages for selectively targeting
self-renewal mechanisms, in particular, HH, Wnt and
Notch signaling pathways in CSCs (Fig. 1).
Activation of HH pathway has been found to be associ-
ated with basal cell carcinoma, glioma and medulloblas-
toma [57]. SONIC Hedgehog (SHH) signaling, mediated
through several components including transmembrane
proteins Patched1 (PTCH1) and Smoothened (SMOH), to
ultimately activate the GLI zinc-finger transcription fac-
tors, is involved in organism development. Increasing evi-
dence has demonstrated that dysregulation of SHH signaling
occurs in multiple cancer types including PCa. It is also
affirmed that SHH signaling has a critical role in progression
of PCa. Sanchez et al. [58] demonstrated that SHH-GLI
signaling components are highly elevated in PCa,
compared to normal prostatic epithelia. Moreover, inter-
ference with the SHH-GLI pathways by using cyclopamine or
anti-SHH antibodies can inhibit proliferation of GLIþ/PSAþ
primary prostate tumor cultures, suggesting that this
autocrine regulation of SHH signaling may be critical to
sustain PCa growth.
Notch is a signaling mechanism that regulates cell fate
specification, embryogenesis pattern formation, stem cell
maintenance and initiation of differentiation in many tis-
sues. Aberrant activation of Notch signaling may lead to
uncontrolled proliferation, restricted differentiation and
prevention of apoptosis in CSCs. Many studies have docu-
mented a consistent deregulation of Notch signaling com-
ponents in PCa cell lines, genetically engineered mouse PCa
models and human PCa specimens. It has been shown that
several Notch signaling components including Notch2,
Notch3, Notch4 and Jagged-1 are expressed in PCa cell lines
such as LNCaP, C4-2B, DU145, and PC3. In addition, the
study done by Zhang et al. [59] showed that Jagged-1
contributed to PCa cell growth by regulation of CDK2 ki-
nase activity. Moreover, Zhu et al. [60] demonstrated that
jagged-1 and Notch-1 were highly elevated in metastatic
and high grade PCa tumors. Moreover, Domingo-Domenech
et al. [61] demonstrated that docetaxel-resistant CRPC
Figure 1 Self-renewal pathways in CSCs (A) Wnt signaling pathway, (B) SONIC Hedgehog signaling pathway, and (C) Notch
signaling pathway. CSCs, cancer stem cells.
Table 2 List of tumor suppressive miRNAs related with
PCSC.
miRNA Known targets
Let-7 EZH2
miR-34a CD44
miR-143 FNDC3B
miR-320 b-catenin
miR-100 c-Myc, Oct4 and Klf4
miR-145-5p Sox2
miR-200b ZEB1, Bmi-1
PCSC, prostate cancer stem cells.
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inhibition of both Notch (by DBZ) and HH (by cyclopamine)
signaling led to depletion of docetaxel-resistant DU145 and
CWR22Rv1 cancer cells through inhibition of Akt and Bcl-2.
Also, Notch pathway has been found to be associated with
embryonal brain tumor by the depletion of CSCs via sup-
pression of notch signaling [62].
Wnt signaling is an evolutionarily conserved develop-
mental pathway, which determines cell fate and controls
stem cells during development. Bisson and Prowse [63]
demonstrated that Wnt signaling is critical for prosta-
sphere formation and self-renewal of PCa cells. In addition
to Wnt3, they observed a significant increase of b-catenin,
keratin 18, CD133 and CD44 expression in PCa, accompa-
nied by increased prostasphere size and enhanced self-
renewal capacity. This evidence suggests that Wnt
signaling regulates the self-renewal of PCSCs. Moreover,
Lee et al. [64] demonstrated that a small molecule nuclear
b-catenin inhibitor (C3) can suppress both AR and b-catenin
signaling pathway, accompanied by diminished AR/b-cat-
enin target gene expression and ablation of PCa cell
growth.
5.3. Targeting ABC transporters involving in CSCs
drug resistance
One of the mechanisms for CSCs to confer resistance to
chemotherapy is by enhanced expression of the ABC
transporter, which can allow CSCs to pump small molecules
such as chemotherapeutic drugs by ATP hydrolysis out of
the cells. For example, Zhang et al. [44] demonstrated that
the PCa cell-derived tumor spheres with elevated levels of
CSCs markers (Gli1, Bmi1 and CD44), had also developed
chemo-resistance due to the elevated levels of ABCG2.
5.4. Manipulation of miRNA
Emerging evidence demonstrates that CSCs are the critical
drivers of tumor progression and metastasis. MicroRNAs
(miRNAs) may play a crucial role in repressing or promoting
metastasis by regulating CSCs. Accumulating studies have
shown that deregulation of miRNA is associated with the
tumor initiation and progression of PCa (Table 2). In
particular, the emergence of CRPC could be attributed to
the existence of PCSCs. Therefore, targeting miRNA regu-
lation has become a novel strategy to dissect the initiation
of PCa.By profiling miRNA expression, Liu et al. [65] found that
several tumor suppressive miRNAs, such as miR-34a, let-7b,
miR-106a and miR-141, were significantly down-regulated
in various stemprogenitor cell populations in PCa. Along
with this finding, they also demonstrated that let-7 can
inhibit PCa cell clonal expansion and tumor regeneration.
Kong et al. [40] found an inverse correlation between let-7
and EZH2 in PCa. Let-7 can suppress clonogenic ability and
sphere-forming capacity of PCa cells by inhibiting EZH2
expression.
There is conflicting evidence, however, on the role of
some miRNAs in PCSC growth and expansion. PCSCs with
clonogenic, tumor-initiating and metastatic capacities, like
many other CSCs, are enriched in the CD44þ cell popula-
tion. Liu et al. [66] demonstrated that miR-34a, a p53-
regulated miRNA, was able to suppress CD44 mRNA
expression, thus, systemic delivery of miR-34a could inhibit
PCa metastasis and regeneration. However, Cheng et al.
[76] found that mice with prostate epithelia-specific acti-
vation of miR-34a and p53, show expansion of the PCSC
compartment, accompanied by a development of early
invasive adenocarcinoma and high-grade prostatic intra-
epithelial neoplasia. Consistently, loss of both miR-34 and
p53 led to the acceleration of MET-dependent growth, self-
renewal, and motility of prostate stemprogenitor cells.
On the other hand, using microarray and reverse tran-
scription polymerase chain reaction analysis, Fan et al. [67]
profiled the miRNA expression in the prostate PC-3 sphere
vs. adherent cells and found that miR-143 level was
increased during the differentiation of PCSCs, which pro-
moted PCa metastasis by repressing Fibronectin type III
domain containing 3B (FNDC3B) expression.
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significantly down-regulated in PCa. By profiling the global
gene expression in PCa cells transfected with miR-320, they
found both CSC markers and downstream target genes of
Wnt/b-catenin pathway are significantly repressed. On the
contrary, knockdown of miR-320 significantly increases the
CSC-like properties, such as tumor sphere formation, che-
moresistance and tumorigenicity. This study demonstrates
that miR-320 is a key negative regulator in PCSC and has the
potential to become a novel therapeutic agent for PCa.
Wang et al. [77] reported that miR-100 negatively regu-
lated migration, invasion, epithelial-to-mesenchymal tran-
sition, colony formation, spheroid formation and expression
of the stem cell factors including c-Myc, Oct4 and Klf4 in PC-
3 and DU145 cells. On the other hand, Huang et al. [69]
reported that miR-143 and miR-145 could suppress in vitro
tumor sphere formation and the expression of CSC markers
factors (CD133, CD44, Oct4, c-Myc and Klf4) in PC-3 cells,
which also correlated with the inhibition of bone invasion of
PC-3 cells in vivo. Overall, these findings demonstrate that
miR-143 and miR-145 play a crucial role in the bone
metastasis by PCa by regulating CSC characteristics.
Furthermore, Yu et al. [70] showed that overexpressing
miR-200b can suppress PCa cell proliferation and migration
and enhance sensitivity to docetaxel by targeting B-cell-spe-
cific Moloney murine leukemia virus insertion site 1 (Bmi-1).
5.5. Immunological targeting of CSCs
Recently, adoptive T-cell immunotherapy using autologous
or allogeneic tumor reactive lymphocytes has been applied
to treat cancer patients with refractory metastatic mela-
noma. This approach has demonstrated efficient tumor
regression [71]. Since tumor-infiltrating lymphocytes with
tumor-specific receptors can be generated from cancer
patients, researchers can utilize this machinery and
improve adoptive T cell therapy by introducing specific
antigen receptors, either tumor-specific T-cell receptors or
chimeric antigen receptors (CAR, composed of an antibody-
based external receptor structure and intracellular T-cell
signaling domains), into these circulating lymphocytes.
Since CARs can induce T cells to attack tumors in a MHC-
unrestricted manner, the application of adoptive T cell
therapy has been expanded to treat multiple cancers such
as lymphoma, chronic lymphocytic leukemia, melanoma,
and neuroblastoma [72e74]. Since CSCs are more resistant
to radiotherapy and chemotherapy, researchers have begun
to examine the possibility of immunotherapies targeting
CSCs. In a recent study, Deng et al. [75] developed a novel
immunotherapy strategy targeting a specific CSC antigen,
epithelial cell adhesion molecule (EpCAM). They introduced
EpCAM-specific CARs into the human peripheral blood
lymphocytes (PBLs), and demonstrated that CAR-expressing
PBLs can not only kill PC3 tumor with high level of EpCAM,
but can also significantly inhibit the growth of PC3 tumor
with low EpCAM.
6. Conclusion
Therapeutic resistance continues to be a problem in the
treatment of PCa and PCSCs are likely an important factorin the development of therapeutic resistance, resulting in
poor survival of PCa patients.The concept of CSCs reflecting
hierarchic tumor organization has underlying important
clinical implications and is supported by many efforts
unveiling potential mechanisms associated with CSCs.
Despite the progress, there are key issues that need to be
addressed, such as identification of PCSC markers, under-
standing the interaction between PCSCs and their micro-
environment. It is therefore, critical to gain a better
understanding of the mechanisms involved in the mecha-
nisms of resistance of PCSC to conventional therapies which
would result in innovative therapeutic approaches.Conflicts of interest
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